Europe PMC
Nothing Special   »   [go: up one dir, main page]

Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Pretreatment MicroRNA Level and Outcome in Sorafenib-treated Hepatocellular Carcinoma.

Author information

Affiliations

  • 1. Second Department of Pathology, Semmelweis University, Budapest, Hungary (BG, BJ, ES, ZS, AK)MTA-SE Tumor Progression Research Group, Hungarian Academy of Sciences, Budapest, Hungary (ZS)Department of Oncology, United Saint Stephen and Saint Laslo Hospital and Outpatient Clinics, Budapest, Hungary (ÉV, GB)ARC-NET Research Centre, Department of Pathology and Diagnostic, Policlinico GB Rossi, University of Verona, Verona, Italy (MF).
      Authors
    • Gyöngyösi B 1
    • Végh É 1
    • Járay B 1
    • Székely E 1
    • Fassan M 1
    • Bodoky G 1
    • Schaff Z 1
    (7 authors)
  • 2. Second Department of Pathology, Semmelweis University, Budapest, Hungary (BG, BJ, ES, ZS, AK)MTA-SE Tumor Progression Research Group, Hungarian Academy of Sciences, Budapest, Hungary (ZS)Department of Oncology, United Saint Stephen and Saint Laslo Hospital and Outpatient Clinics, Budapest, Hungary (ÉV, GB)ARC-NET Research Centre, Department of Pathology and Diagnostic, Policlinico GB Rossi, University of Verona, Verona, Italy (MF)
      Authors
    • Kiss A 2
    (1 author)

ORCIDs linked to this article

The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society, 07 May 2014, 62(8):547-555
https://doi.org/10.1369/0022155414537277 PMID: 24804874 

Abstract 

Sorafenib represents the first effective targeted therapy for advanced stage hepatocellular carcinoma (HCC); however, adequate patient stratification regarding sorafenib-responsiveness is still missing. Our aim was to analyse the association between the pretreatment microRNA profile of HCC and patient survival under sorafenib treatment. Total RNA was extracted from diagnostic fine-needle aspiration biopsy (FNAB) cytological smears of 20 advanced stage HCC patients collected between June 2008 and July 2012. All patients underwent sorafenib administration after FNA. Clinicopathological and survival data were recorded. Fourteen frequently deregulated miRNAs in HCC (miR-17-5p, miR-18a, miR-21, miR-34a, miR-122, miR-195, miR-210, miR-214, miR-221, miR-222, miR-223, miR-224, miR-140, miR-328) were tested by qRT-PCR. NormFinder software was used to select proper miR (mir-140) as a reference. Satisfactory amount of total RNA was obtained from all the considered samples (mean 10.8 ± 9.3 µg, range 0.2-32.2 µg). Among the analysed miRNAs, high miR-214 expression was associated with smaller tumor size (p=0.019), whereas high miR-17-5p expression correlated with better Eastern Cooperative Oncology Group performance status (p=0.003). The survival analysis revealed that high miR-224 expression was associated with increased progression-free and overall survival (PFS p=0.029; OS p=0.012). Pretreatment microRNA profiling, especially miR-224 expression, might serve as an ancillary tool for the better assessment of expected survival rates for patients under sorafenib treatment.

Full text links 

Read article at publisher's site: https://doi.org/10.1369/0022155414537277

Read article for free, from open access legal sources, via Unpaywall: https://journals.sagepub.com/doi/pdf/10.1369/0022155414537277Unpaywall

References 

Articles referenced by this article (48)

Show 10 more references (10 of 48)

Citations & impact 

Impact metrics

31
Citations
Jump to Citations

Citations of article over time

Article citations

Go to all (31) article citations

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.